Previous 10 | Next 10 |
ANI Pharmaceuticals (NASDAQ: ANIP ) initiated with Buy rating and $76 (9% upside) price target at Guggenheim. More news on: ANI Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
EVANSTON, Ill., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Rachel Sherman, M.D., M.P.H., former pri...
EVANSTON, Ill., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of preclinical data on its novel NMDA recep...
Aurora Cannabis (NYSE: ACB ) initiated with Neutral rating and $7 (6% upside) price target at Piper Jaffray. More news on: Aurora Cannabis Inc., CV Sciences, Inc., Coherus BioSciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Aptinyx Inc. (APTX) Q2 2019 Results Earnings Conference Call August 12, 2019, 08:00 AM ET Company Participants Nick Smith - Senior Director, Corporate Development and Investor Relations Norbert Riedel - President & CEO Ashish Khanna - CFO & Chief Business Officer Andy K...
Aptinyx ( APTX ) Q2 results : Revenues: $0.9M (-57.1%). More news on: Aptinyx Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Aptinyx (NASDAQ: APTX ): Q2 GAAP EPS of -$0.36 beats by $0.16 . More news on: Aptinyx Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates Conference call today at 8:00 a.m. ET EVANSTON, Ill., Aug. 12, 2019 (GLOBE NEWSWIR...
EVANSTON, Ill., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and chief executive of...
EVANSTON, Ill., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live w...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...